AinosAIMD
Market Cap: 5.19M
About: Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Employees: 46
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 0
200% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 0
171% more capital invested
Capital invested by funds: $35.3K [Q4 2023] → $95.4K (+$60.2K) [Q1 2024]
80% more funds holding
Funds holding: 5 [Q4 2023] → 9 (+4) [Q1 2024]
1.04% more ownership
Funds ownership: 0.37% [Q4 2023] → 1.41% (+1.04%) [Q1 2024]
Research analyst outlook
We haven’t received any recent analyst ratings for AIMD.